BioreclamationIVT is now BioIVT

YOUR PARTNER IN ELEVATING SCIENCE

BioIVT, formerly BioreclamationIVT, is a leading global provider of high-quality biological specimens and value-added services. We specialize in control and disease state samples including human and animal tissues, cell products, blood and other biofluids. Our unmatched portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples. 

Our PHASEZERO Research Services team works collaboratively with clients to provide target and biomarker validation, phenotypic assays to characterize novel therapeutics, clinical assay development and in vitro hepatic modeling solutions. And as the world’s premier supplier of ADME-Tox model systems, including hepatocytes and subcellular fractions, BioIVT enables scientists to better understand the pharmacokinetics and drug metabolism of newly discovered compounds and the effects on disease processes. By combining our technical expertise, exceptional customer service, and unparalleled access to biological specimens, BioIVT serves the research community as a trusted partner in ELEVATING SCIENCE.

Learn about the new BioIVT!
BioIVT Corporate Video

VIEW OUR PRODUCTS AND SERVICES

BioIVT is a worldwide provider of human and animal biological specimens and value-added services to pharmaceutical, biotechnology, diagnostic, contract research organizations (CRO),  academic and government institutions.

Looking for a Product or Service?

Our new site has over 400 individual product pages featuring the complete capabilities of BioIVT.

Visit our Request A Quote page to learn how to find your product or service of interest.

FROM THE BLOG

AACR 2018 – Hot Topics

By Cathie Miller, Ph.D. / June 12, 2018

At this year’s 110th AACR, Immuno-oncology was the topic of many discussions including seven out of eleven plenary sessions. Biggest of all was the lung cancer plenary session that discussed potentially standard-of-care-changing results from Merck, BMS, and Roche in relation to PD-L1 biomarker-related first-line treatment of metastatic non-small cell lung cancer. BioIVT hosted a special… Read more »

Read More >